LLY

1,045.45

-1.17%↓

JNJ

209.98

-1.92%↓

ABBV

222.91

-1.68%↓

UNH

334.82

-1.5%↓

AZN

90.56

-0.61%↓

LLY

1,045.45

-1.17%↓

JNJ

209.98

-1.92%↓

ABBV

222.91

-1.68%↓

UNH

334.82

-1.5%↓

AZN

90.56

-0.61%↓

LLY

1,045.45

-1.17%↓

JNJ

209.98

-1.92%↓

ABBV

222.91

-1.68%↓

UNH

334.82

-1.5%↓

AZN

90.56

-0.61%↓

LLY

1,045.45

-1.17%↓

JNJ

209.98

-1.92%↓

ABBV

222.91

-1.68%↓

UNH

334.82

-1.5%↓

AZN

90.56

-0.61%↓

LLY

1,045.45

-1.17%↓

JNJ

209.98

-1.92%↓

ABBV

222.91

-1.68%↓

UNH

334.82

-1.5%↓

AZN

90.56

-0.61%↓

Home・Aktien・Revvity Inc

Revvity Inc

Open

BrancheGesundheitswesen

96.74 -0.91

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

96.37

Max

99.43

Schlüsselkennzahlen
By Trading Economics
Einkommen	-8.6M 47M
Verkäufe	-21M 699M
KGV Branchendurchschnitt	51.438 77.671
EPS	0.4
Dividendenrendite	0.28
Gewinnspanne	6.675
Angestellte	11,000
EBITDA	-14M 181M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+11.81% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	0.28% 2.35%
Nächstes Ex-Dividendendatum	16. Jan. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	305M 12B
Vorheriger Eröffnungskurs	97.65
Vorheriger Schlusskurs	96.74

Nachrichtenstimmung

By Acuity

26%

74%

48 / 374 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Revvity Inc Prognose

Kursziel

By TipRanks

11.81% Vorteil

12-Monats-Prognose

Durchschnitt 112.36 USD 11.81%

Hoch 125 USD

Tief 100 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Revvity Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Revvity Inc – Dist abgegeben haben.

Stimmung

By Acuity

48 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.